Cost-effectiveness comparison of cabozantinib with everolimus, axitinib, and nivolumab in the treatment of advanced renal cell carcinoma following the failure of prior therapy in England

Cost-effectiveness comparison of cabozantinib with everolimus, axitinib, and nivolumab in the treatment of advanced renal cell carcinoma following the failure of prior therapy in England

Jie Meng,1 Johanna Lister,1 Anne-Lise Vataire,2 Roman Casciano,1 Jerome Dinet2 1Analytica Laser, London, UK; 2Ipsen Pharma, Boulogne-Billancourt, France Purpose: The aim of this study was to compare the cost-effectiveness of cabozantinib with the standard of care in England in adult patients with ad...

Full description

Bibliographic Details
Main Authors: Meng J, Lister J, Vataire AL, Casciano R, Dinet J
Format: Article
Language:English
Published: Dove Medical Press 2018-04-01
Series:ClinicoEconomics and Outcomes Research
Subjects:
incremental cost-effectiveness ratio
health economic analysis
health care costs
kidney cancer
targeted therapy
Online Access:https://www.dovepress.com/cost-effectiveness-comparison-of-cabozantinib-with-everolimus-axitinib-peer-reviewed-article-CEOR

Internet

https://www.dovepress.com/cost-effectiveness-comparison-of-cabozantinib-with-everolimus-axitinib-peer-reviewed-article-CEOR

Similar Items